BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 1,200 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $85.64, for a total transaction of $102,768.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at $80.76 on Wednesday. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a twelve month low of $79.50 and a twelve month high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.02 EPS. research analysts forecast that BioMarin Pharmaceutical Inc. will post -0.65 EPS for the current fiscal year.

Several research analysts have recently weighed in on the stock. Evercore ISI assumed coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, August 16th. They set an “outperform” rating and a $100.00 price objective on the stock. Leerink Swann restated an “outperform” rating and set a $142.00 price objective (up from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. Piper Jaffray Companies restated a “buy” rating and set a $113.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. SunTrust Banks set a $115.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, October 19th. Finally, BMO Capital Markets reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Friday, September 15th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $111.59.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cigna Investments Inc. New boosted its holdings in BioMarin Pharmaceutical by 1.5% in the 2nd quarter. Cigna Investments Inc. New now owns 2,377 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 36 shares during the period. Daiwa Securities Group Inc. boosted its holdings in BioMarin Pharmaceutical by 1.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 4,950 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 50 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in BioMarin Pharmaceutical by 1.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,126 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 54 shares during the period. NGAM Advisors L.P. boosted its holdings in BioMarin Pharmaceutical by 0.4% in the 2nd quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock valued at $1,385,000 after purchasing an additional 55 shares during the period. Finally, Symphony Asset Management LLC boosted its holdings in BioMarin Pharmaceutical by 1.1% in the 2nd quarter. Symphony Asset Management LLC now owns 6,465 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 73 shares during the period. 99.26% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/06/george-eric-davis-sells-1200-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.